Tenaya Therapeutics, Inc.
NASDAQ:TNYA
1.47 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 8.687 | 8.713 | 4.025 | 2.483 | 1.989 |
| Gross Profit
| -8.687 | -8.713 | -4.025 | -2.483 | -1.989 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 98.038 | 94.537 | 54.393 | 31.099 | 23.148 |
| General & Administrative Expenses
| 33.155 | 31.084 | 18.413 | 7.813 | 4.564 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 33.155 | 31.084 | 18.413 | 7.813 | 4.564 |
| Other Expenses
| 0 | 0.002 | -0.023 | 0.43 | 1.028 |
| Operating Expenses
| 131.193 | 125.621 | 72.806 | 38.912 | 27.712 |
| Operating Income
| -131.193 | -125.621 | -72.806 | -38.912 | -27.712 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 7.109 | 1.956 | 0.085 | 0.517 | 1.481 |
| Income Before Tax
| -124.084 | -123.665 | -72.721 | -38.395 | -26.231 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.002 | -3.069 | -0.087 | -0.453 |
| Net Income
| -124.084 | -123.663 | -69.652 | -38.308 | -25.778 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| EPS Diluted
| -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| EBITDA
| -122.506 | -114.952 | -68.696 | -36.429 | -25.723 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |